Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$3.30 +8.6%	$2.81	$0.40 ▼ $5.48	$56.04M	0.27	219,132 shs	239,759 shs
APM Aptorum Group	$1.39 -4.8%	$1.26	$0.46 ▼ $7.49	$7.81M	-0.1	252,620 shs	52,096 shs
BRNS Barinthus Biotherapeutics	$1.26 -1.6%	$1.19	$0.64 ▼ $2.92	$51.47M	-0.73	257,821 shs	13,541 shs
PHGE BiomX	$0.56 -24.9%	$0.45	$0.34 ▼ $2.40	$12.99M	1.42	347,190 shs	53,300 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	+8.55%	+22.22%	-6.25%	+122.97%	+340.06%
APM Aptorum Group	-4.79%	+10.32%	-28.35%	+45.99%	-57.62%
BRNS Barinthus Biotherapeutics	-1.64%	-6.34%	-11.62%	+32.94%	-5.64%
PHGE BiomX	+8.61%	+16.35%	+39.45%	+2.78%	-69.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVC ABVC BioPharma	0.4123 of 5 stars	0.0	3.0	2.3	0.8	0.0
APM Aptorum Group	0.832 of 5 stars	0.0	2.0	3.0	1.7	0.6
BRNS Barinthus Biotherapeutics	2.7116 of 5 stars	3.5	3.0	1.9	0.8	1.3
PHGE BiomX	2.4455 of 5 stars	3.5	0.0	2.1	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	0.00	N/A	N/A	N/A
APM Aptorum Group	0.00	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	3.00	Buy	$3.00	139.04% Upside
PHGE BiomX	3.00	Buy	$21.00	3,683.78% Upside

Current Analyst Ratings Breakdown

Latest PHGE, APM, ABVC, and BRNS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/16/2025	PHGE BiomX	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$391.24K	143.24	N/A	N/A	$0.56 per share	5.89
APM Aptorum Group	$430K	17.29	N/A	N/A	$2.20 per share	0.63
BRNS Barinthus Biotherapeutics	$14.97M	3.38	N/A	N/A	$2.54 per share	0.49
PHGE BiomX	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$4.90M	-$0.17	N/A	∞	N/A	-963.46%	-46.76%	-23.02%	N/A
APM Aptorum Group	-$4.27M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	-$61.07M	-$1.73	N/A	N/A	N/A	N/A	-54.70%	-44.75%	N/A
PHGE BiomX	-$28.32M	-$1.36	N/A	N/A	N/A	N/A	-127.82%	-56.50%	N/A

Latest PHGE, APM, ABVC, and BRNS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	ABVC ABVC BioPharma	N/A	-$0.13	N/A	-$0.13	N/A	N/A
8/7/2025	Q2 2025	BRNS Barinthus Biotherapeutics	-$0.29	-$0.52	-$0.23	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.42	0.22
APM Aptorum Group	N/A	0.22	0.22
BRNS Barinthus Biotherapeutics	N/A	7.89	7.89
PHGE BiomX	0.51	2.84	2.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
APM Aptorum Group	3.80%
BRNS Barinthus Biotherapeutics	25.20%
PHGE BiomX	40.57%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	17.10%
APM Aptorum Group	63.99%
BRNS Barinthus Biotherapeutics	10.70%
PHGE BiomX	1.17%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	16.98 million	14.08 million	Not Optionable
APM Aptorum Group	30	5.35 million	1.93 million	Not Optionable
BRNS Barinthus Biotherapeutics	107	40.34 million	36.02 million	N/A
PHGE BiomX	120	26.18 million	44.04 million	Not Optionable

PHGE, APM, ABVC, and BRNS Headlines

Recent News About These Companies

BiomX Posts Q2 Loss With 14% Cost Drop

August 14 at 2:55 AM | aol.comA

BiomX Inc. (PHGE) Q2 2025 Earnings Call Transcript

August 13 at 12:06 PM | seekingalpha.com

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

August 13 at 6:30 AM | globenewswire.com

What to Expect from BiomX's Earnings

August 12, 2025 | benzinga.com

BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

August 6, 2025 | globenewswire.com

BiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapy

July 14, 2025 | investing.com

BiomX Shares Surge 60% Following Start of Phase 2b Trial for Cystic Fibrosis Treatment

July 14, 2025 | msn.com

PHGE | BiomX Inc. Stock Overview (U.S.: NYSE American) | Barron's

July 14, 2025 | barrons.com

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

July 14, 2025 | globenewswire.com

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

July 8, 2025 | globenewswire.com

BiomX Inc. to Present Positive Phase 2 Results for BX211 at Biomed Israel 2025 Conference

May 21, 2025 | nasdaq.com

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

May 19, 2025 | globenewswire.com

BiomX Inc. (AMEX:PHGE) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

May 15, 2025 | globenewswire.com

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

May 8, 2025 | globenewswire.com

BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

April 18, 2025 | zacks.com

BiomX announces going concern qualification from independent audit

April 1, 2025 | markets.businessinsider.com

BiomX target adjusted to $21 from $2 at H.C. Wainwright

April 1, 2025 | markets.businessinsider.com

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

April 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHGE, APM, ABVC, and BRNS Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$3.30 +0.26 (+8.55%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.28 -0.02 (-0.76%)

As of 08/15/2025 07:15 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Aptorum Group NASDAQ:APM

$1.39 -0.07 (-4.79%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.40 +0.01 (+0.72%)

As of 08/15/2025 06:48 PM Eastern

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Barinthus Biotherapeutics NASDAQ:BRNS

$1.25 -0.02 (-1.64%)

Closing price 08/15/2025 03:36 PM Eastern

Extended Trading

$1.24 -0.01 (-1.20%)

As of 08/15/2025 06:41 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

BiomX NYSEMKT:PHGE

$0.56 -0.18 (-24.90%)

Closing price 08/15/2025 03:55 PM Eastern

Extended Trading

$0.54 -0.02 (-2.88%)

As of 08/15/2025 07:54 PM Eastern

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time